Loading…
Reliance Pharma Fund
Disclosed for 84 months, Sep 2012 to Aug 2019. This scheme is no longer reporting.Published as: RELIANCE PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹1,948 Cr
up ₹154 Cr vs Nov 2017
Reliance Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In December 2017 it disclosed 19 stocks worth ₹1,948 Cr, up ₹154 Cr from Nov 2017. Its largest positions were Divi's Laboratories Limited (11.3%), Abbott India Limited (9.4%), Biocon Limited (9.4%); the ten largest together made up 81.1% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 83.0% of its equity. Cash and debt stood at 2.0%. Compared with Nov 2017 the fund entered 0 new stocks and exited 0.
Against 227 other Sectoral / Thematic funds
Concentration
99%
Top-10 weight is higher than 99% of peers
Breadth
4%
Holds more stocks than 4% of peers
Cash
30%
Holds more cash than 30% of peers
Holdings in December 2017
Download CSVEvery line the fund disclosed, with the change against Nov 2017. Click a column to sort; click a company to see every fund that owns it.
| Divi's Laboratories Limited | 11.28% | down 0.33 pts | ₹220 Cr | up ₹11.5 Cr | Added |
| Abbott India Limited | 9.37% | down 0.34 pts | ₹183 Cr | up ₹8.3 Cr | Added |
| Biocon Limited | 9.36% | up 1.19 pts | ₹182 Cr | up ₹35.7 Cr | Added |
| Cipla Limited | 8.44% | down 0.27 pts | ₹164 Cr | up ₹8.1 Cr | Added |
| Sun Pharmaceutical Industries Limited | 8.36% | down 0.22 pts | ₹163 Cr | up ₹8.9 Cr | Added |
| Dr. Reddy's Laboratories Limited | 8.31% | down 0.22 pts | ₹162 Cr | up ₹8.7 Cr | Added |
| Sanofi India Limited | 7.67% | up 0.17 pts | ₹149 Cr | up ₹14.8 Cr | Added |
| Aurobindo Pharma Limited | 7.06% | down 0.66 pts | ₹138 Cr | down ₹98 L | Trimmed |
| Thyrocare Technologies Limited | 6.59% | up 0.56 pts | ₹128 Cr | up ₹20.2 Cr | Added |
| Torrent Pharmaceuticals Limited | 4.69% | up 0.07 pts | ₹91.3 Cr | up ₹8.5 Cr | Added |
| Lupin Limited | 3.86% | down 0.01 pts | ₹75.2 Cr | up ₹5.7 Cr | Added |
| Healthcare Global Enterprises Limited | 2.51% | down 0.35 pts | ₹49 Cr | down ₹2.4 Cr | Trimmed |
| Glenmark Pharmaceuticals Limited | 2.14% | down 0.06 pts | ₹41.6 Cr | up ₹2.1 Cr | Added |
| Narayana Hrudayalaya Limited | 1.97% | down 0.17 pts | ₹38.4 Cr | down ₹9 L | Held |
| Max India Limited | 1.82% | down 0.37 pts | ₹35.4 Cr | down ₹3.8 Cr | Trimmed |
| Apollo Hospitals Enterprise Limited | 1.78% | up 0.01 pts | ₹34.8 Cr | up ₹2.8 Cr | Added |
| Cash, TREPS & receivables | 1.71% | up 0.44 pts | ₹33.2 Cr | up ₹10.5 Cr | Added |
| Indoco Remedies Limited | 1.47% | up 0.36 pts | ₹28.7 Cr | up ₹8.7 Cr | Added |
| Alkem Laboratories Limited | 0.80% | up 0.02 pts | ₹15.5 Cr | up ₹1.5 Cr | Added |
| Syngene International Limited | 0.56% | down 0.06 pts | ₹10.8 Cr | down ₹25 L | Trimmed |
| Axis Bank Limited Money market | 0.26% | up 0.26 pts | ₹5 Cr | up ₹5 Cr | New |
What changed, Nov 2017 to Dec 2017
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Biocon Limitedup ₹35.7 Cr (+1.19% pts)
- Thyrocare Technologies Limitedup ₹20.2 Cr (+0.56% pts)
- Sanofi India Limitedup ₹14.8 Cr (+0.17% pts)
- Divi's Laboratories Limitedup ₹11.5 Cr (−0.33% pts)
- Sun Pharmaceutical Industries Limited ₹8.9 Cr (−0.22% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Nov 2017, the weight rose most in Pharmaceuticals (+0.4 pts), and fell most in Healthcare Services (−0.3 pts).
- Pharmaceuticals1.1% → 1.5%+0.4 pts
- Healthcare Services15.8% → 15.5%−0.3 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Dec 2014 | Dec 2016 | Jun 2017 | Sep 2017 | Nov 2017 | Dec 2017 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 93.0% | 83.8% | 86.0% | 84.4% | 83.1% | 83.0% |
| Healthcare Services | — | 16.2% | 14.0% | 15.6% | 15.8% | 15.5% |
| Pharmaceuticals | 6.3% | — | — | — | 1.1% | 1.5% |
Allocation in Dec 2017change vs Nov 2017
- Pharmaceuticals & Biotechnology (12)83.0%▼ 0.1 pts
- Healthcare Services (6)15.5%▼ 0.3 pts
- Pharmaceuticals (1)1.5%▲ 0.4 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal.
Cash & debt, Dec 2017
2.0%
▲ 0.7 pts vs Nov 2017
- Cash alone
- 1.7%
- cash and net receivables
- A year earlier
- 0.4%
- Dec 2016 · now ▲ 1.6 pts
- Last 12 months
- 0.4% – 5.8%
- lowest to highest · record 9.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.